BACKGROUND Low-molecular-weight heparins are effective for treating venous thrombosis, but their cost-effectiveness has not been rigorously assessed. OBJECTIVE To evaluate the cost-effectiveness of low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. DESIGN Decision model. DATA SOURCES Probabilities for clinical outcomes were ob...

1 Amirkhosravi A, Mousa SA, Amaya M, et al. Antimetastatic effect of tinzaparin, a low-molecular-weight heparin. J Thromb Haemost 2003; 1:1972–1976 2 Mousa SA, Mohamed S. Antiangiogenic mechanisms and efficacy of the low molecular weight heparin, tinzaparin: anti-cancer efficacy. Oncol Rep 2004; 12:683–688 3 Von Tempelhoff GF, Harenberg J, Nieman F, et al. Effect of low-molecular weight heparin...

ment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Circulation 1998; 97: 1702–7. [13] Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997; 337: 668–98. [14] Fareed J, Jeskie W, Hoppensteadt D, Clarizo R, Walenga JM. Are the available low-molecular-weight heparin preparations the s...

heparin is frequently used in different clinical settings to reduce the coagulating ability of the blood. because of probable adverse effects owing to heparin therapy and regarding variability of patients’ responses to heparin, which make it very unreliable, it seems prudent to monitor meticulously its effects on the human body. there are a lot of laboratory tests to watch its effects on the bo...

  Background: Low molecular weight heparin (LMWH) is used for the treatment and prevention of coagulative disorders. Few patients receiving therapeutic doses of LMWH develop major hemorrhage. Currently there are few reports in the literature on acute overdose on adults.  In this study, clinical profile, treatment and outcome of 21 patients who acutely overdosed enoxaparin are described. Method...

BACKGROUND AND PURPOSE There is no consensus whether to use unfractionated heparin or low-molecular weight heparin for the treatment of cerebral venous thrombosis. We examined the effect on clinical outcome of each type of heparin. METHODS A nonrandomized comparison of a prospective cohort study (the International Study on Cerebral Vein and Dural Sinus Thrombosis) of 624 patients with cerebra...

low molecular weight heparin-modified isoliquiritigenin-loaded solid lipid nanoparticle (lmwh-isl-sln) was developed for injective application. the morphological observation, particle diameter and zeta potential of lmwh-isl-sln were characterized using transmission electron microscopy (tem) and a malvern zetasizer. its entrapment efficiency (ee) and drug loading (dl) were determined by ultracen...

BACKGROUND Pulmonary embolism (PE) occurs in 50% or more of patients with proximal deep-vein thrombosis. Low-molecular-weight heparin treatment is effective and safe in patients with deep vein thrombosis and may also be so in patients with PE. Recent rigorous clinical trials have established objective criteria for determining a high probability of PE by perfusion lung scanning. OBJECTIVE To c...